Dear readers
Another new oncology journal? We say definitely and with full conviction: Yes! InFo ONKOLOGIE & HÄMATOLOGIE provides you with the latest news and views in oncology: 10 times a year, national and international key opinion leaders and a professional editorial team report on what is happening in oncology and hematology in a practical, scientific and always up-to-date way.
10 times a year – this frequency is unique in Switzerland!
Each issue is characterized by a thematic focus on the diagnosis and therapy of a tumor entity. In this first issue of the magazine, three articles are devoted to lung cancer. Review articles on complementary topics expand the spectrum of content in each case. Currently, fatigue in cancer is presented in the section “Medizin aktuell”.
In addition to key opinion leaders, the editorial team provides you with important information. They interview specialists and probe where questions have so far remained unanswered. We start with Prof. Christoph Driessen, MD, Head of the Department of Oncology/Hematology at the Cantonal Hospital of St. Gallen, who answers questions on pathogenesis, diagnosis and research innovations in the field of non-Hodgkin’s lymphoma (NHL).
We also attend all major international as well as the smaller but no less relevant national oncology and hematology congresses for you, so that you are always informed about the latest oncological developments and achievements. In November, for example, the 5th Interdisciplinary Prostate Cancer Symposium was held in St. Gallen.
We also attended major events such as the DGHO, ESMO and ASCO congresses for you. So look forward to the detailed congress highlights, which always feature prominently in InFo ONKOLOGIE & HÄMATOLOGIE!
Another highlight: The articles are bilingual, i.e. the title, introduction and take-home messages are printed in German and French respectively. This enables an optimal exchange of knowledge across both language regions.
Are you also convinced? Then subscribe to InFo ONKOLOGIE & HÄMATOLOGIE today and benefit from our innovative subscription bonuses. For more details, please refer to page 7.
Now I hope you enjoy reading the new InFo ONKOLOGIE & HÄMATOLOGIE.about a feedback on sb@primemedic.ch I am very happy!
Cordially yours
Séverine Bonini, Editor-in-Chief
InFo Oncology & Hematology 2013; 1(1): 1
